DE19954843C2 - Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung - Google Patents
Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren VerwendungInfo
- Publication number
- DE19954843C2 DE19954843C2 DE19954843A DE19954843A DE19954843C2 DE 19954843 C2 DE19954843 C2 DE 19954843C2 DE 19954843 A DE19954843 A DE 19954843A DE 19954843 A DE19954843 A DE 19954843A DE 19954843 C2 DE19954843 C2 DE 19954843C2
- Authority
- DE
- Germany
- Prior art keywords
- protein
- membrane
- peptide
- liposomes
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 68
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 66
- 239000002502 liposome Substances 0.000 title claims abstract description 63
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 31
- 230000008569 process Effects 0.000 title description 19
- 239000000126 substance Substances 0.000 claims abstract description 31
- 239000012528 membrane Substances 0.000 claims abstract description 30
- 230000002441 reversible effect Effects 0.000 claims abstract description 4
- 239000012062 aqueous buffer Substances 0.000 claims abstract description 3
- 150000002632 lipids Chemical class 0.000 claims description 18
- 239000002609 medium Substances 0.000 claims description 15
- 230000003993 interaction Effects 0.000 claims description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 6
- -1 alkyl carboxylic acids Chemical class 0.000 claims description 6
- 239000013522 chelant Substances 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- 150000003973 alkyl amines Chemical class 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 150000003573 thiols Chemical group 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000005210 alkyl ammonium group Chemical group 0.000 claims description 2
- 150000001356 alkyl thiols Chemical class 0.000 claims description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 2
- 230000002101 lytic effect Effects 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 2
- 125000004149 thio group Chemical group *S* 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000009920 chelation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 238000005188 flotation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FJYHOEREBAQJLQ-UHFFFAOYSA-N 2,2,2-trinitroacetic acid Chemical class OC(=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O FJYHOEREBAQJLQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- VEACNNAXKZAHQV-UHFFFAOYSA-N lead;2-sulfanylethanol Chemical compound [Pb].OCCS VEACNNAXKZAHQV-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19954843A DE19954843C2 (de) | 1999-11-09 | 1999-11-09 | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung |
| DK00976017T DK1227794T3 (da) | 1999-11-09 | 2000-11-09 | Fremgangsmåde til indkapsling af proteiner eller peptider i liposomer |
| AT00976017T ATE311175T1 (de) | 1999-11-09 | 2000-11-09 | Verfahren zur verkapselung von proteinen oder peptiden in liposomen |
| AU13933/01A AU1393301A (en) | 1999-11-09 | 2000-11-09 | Method for encapsulating proteins or peptides in liposomes, liposomes produced using said method, and their use |
| EP00976017A EP1227794B1 (de) | 1999-11-09 | 2000-11-09 | Verfahren zur verkapselung von proteinen oder peptiden in liposomen |
| JP2001536115A JP2003513901A (ja) | 1999-11-09 | 2000-11-09 | タンパク質又はペプチドをリポソームに封入するための方法及びこの方法で調製されたリポソーム及びその使用 |
| DE50011769T DE50011769D1 (de) | 1999-11-09 | 2000-11-09 | Verfahren zur verkapselung von proteinen oder peptiden in liposomen |
| PCT/EP2000/011079 WO2001034115A2 (de) | 1999-11-09 | 2000-11-09 | Verfahren zur verkapselung von proteinen oder peptiden in liposomen, mit dem verfahren hergestellte liposomen und deren verwendung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19954843A DE19954843C2 (de) | 1999-11-09 | 1999-11-09 | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19954843A1 DE19954843A1 (de) | 2001-05-17 |
| DE19954843C2 true DE19954843C2 (de) | 2003-11-20 |
Family
ID=7929069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19954843A Expired - Fee Related DE19954843C2 (de) | 1999-11-09 | 1999-11-09 | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung |
| DE50011769T Expired - Fee Related DE50011769D1 (de) | 1999-11-09 | 2000-11-09 | Verfahren zur verkapselung von proteinen oder peptiden in liposomen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50011769T Expired - Fee Related DE50011769D1 (de) | 1999-11-09 | 2000-11-09 | Verfahren zur verkapselung von proteinen oder peptiden in liposomen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1227794B1 (https=) |
| JP (1) | JP2003513901A (https=) |
| AT (1) | ATE311175T1 (https=) |
| AU (1) | AU1393301A (https=) |
| DE (2) | DE19954843C2 (https=) |
| DK (1) | DK1227794T3 (https=) |
| WO (1) | WO2001034115A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10152145A1 (de) * | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| EP1585504A4 (en) * | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | Protein stabilized liposomal formulations of pharmaceutical active ingredients |
| WO2004100927A2 (de) * | 2003-05-12 | 2004-11-25 | Novosom Ag | Injizierbare depots aus liposomalen aggregaten zum wirkstoffdelivery |
| US20090297592A1 (en) * | 2005-05-11 | 2009-12-03 | Jcr Pharmaceuticals Co., Ltd. | Lipid Vesicle Composition |
| CN103071209A (zh) | 2005-11-17 | 2013-05-01 | 周吉尼克斯股份有限公司 | 用无针注射递送粘稠制剂 |
| US8268347B1 (en) | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| ES2563061T3 (es) | 2008-04-28 | 2016-03-10 | Zogenix, Inc. | Nuevas formulaciones para el tratamiento de la migraña |
| PL2474306T3 (pl) | 2009-08-31 | 2017-06-30 | Nanocarrier Co., Ltd. | Kompozycja w postaci cząstek stałych i zawierająca ją kompozycja lecznicza |
| JP4653242B1 (ja) | 2010-02-12 | 2011-03-16 | ナノキャリア株式会社 | 粒子状医薬組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2907303A1 (de) * | 1978-02-24 | 1979-09-06 | Demetrios P Papahadjopoulos | Verfahren zur einkapselung biologisch aktiver substanzen |
| JPH06271460A (ja) * | 1993-03-22 | 1994-09-27 | Nippon Oil & Fats Co Ltd | リポソーム分散液の製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342826A (en) * | 1980-02-04 | 1982-08-03 | Collaborative Research, Inc. | Immunoassay products and methods |
| JPS5782310A (en) * | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
| US4933121A (en) * | 1986-12-10 | 1990-06-12 | Ciba Corning Diagnostics Corp. | Process for forming liposomes |
| JPH0717874A (ja) * | 1993-06-18 | 1995-01-20 | Terumo Corp | ヘモグロビン内包リポソーム |
| EP0918539B1 (en) * | 1996-02-16 | 2005-10-19 | Biomira Usa Inc. | Vaccine for b-cell malignancies |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
-
1999
- 1999-11-09 DE DE19954843A patent/DE19954843C2/de not_active Expired - Fee Related
-
2000
- 2000-11-09 WO PCT/EP2000/011079 patent/WO2001034115A2/de not_active Ceased
- 2000-11-09 EP EP00976017A patent/EP1227794B1/de not_active Expired - Lifetime
- 2000-11-09 JP JP2001536115A patent/JP2003513901A/ja active Pending
- 2000-11-09 DK DK00976017T patent/DK1227794T3/da active
- 2000-11-09 DE DE50011769T patent/DE50011769D1/de not_active Expired - Fee Related
- 2000-11-09 AU AU13933/01A patent/AU1393301A/en not_active Abandoned
- 2000-11-09 AT AT00976017T patent/ATE311175T1/de not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2907303A1 (de) * | 1978-02-24 | 1979-09-06 | Demetrios P Papahadjopoulos | Verfahren zur einkapselung biologisch aktiver substanzen |
| JPH06271460A (ja) * | 1993-03-22 | 1994-09-27 | Nippon Oil & Fats Co Ltd | リポソーム分散液の製造方法 |
Non-Patent Citations (1)
| Title |
|---|
| CA 127: 140288r * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50011769D1 (de) | 2006-01-05 |
| WO2001034115A2 (de) | 2001-05-17 |
| DE19954843A1 (de) | 2001-05-17 |
| AU1393301A (en) | 2001-06-06 |
| EP1227794B1 (de) | 2005-11-30 |
| EP1227794A2 (de) | 2002-08-07 |
| WO2001034115A3 (de) | 2001-09-07 |
| JP2003513901A (ja) | 2003-04-15 |
| DK1227794T3 (da) | 2006-04-03 |
| ATE311175T1 (de) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69426884T2 (de) | Verfahren zum kontrollieren der liposomengrösse | |
| DE3650302T2 (de) | Auf alpha-tocopherol basierte bläschen. | |
| EP1363601B1 (de) | Amphotere liposomen und verwendung dieser | |
| EP1289642B2 (de) | Nanokapseln mit einer polyelektrolythülle | |
| DE3587640T2 (de) | Einkapseln antineoplastischer mittel in liposomen. | |
| DE69822176T2 (de) | Peptid/lipid-komplexbildung durch co-lyophilisation | |
| DE3689769T2 (de) | Multilamellare liposome mit verbesserter einschliessungswirkung. | |
| DE60123583T2 (de) | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome | |
| DE69113640T2 (de) | Beladungstechnik zur herstellung arzneistoffhaltiger liposomen. | |
| DD201973A5 (de) | Verfahren zur herstellung von liposomalen arzneimitteln | |
| DE2725696A1 (de) | Synthetisches liposom und verfahren zur herstellung | |
| EP0032578A1 (de) | Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel | |
| DE10109898A1 (de) | Lipide mit veränderlicher Ladung | |
| EP1203614A1 (de) | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln | |
| DE69825137T2 (de) | Liposomale Erythropoietin-Dispersion | |
| DE19954843C2 (de) | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung | |
| DE3001842C2 (https=) | ||
| DE69117029T2 (de) | Verfahren zur herstellung eines durch einbau einer lipophilen wirksubstanz modifizierten lipoproteins | |
| DE60117583T2 (de) | Liposomen welche antikanzeröse wirkstoffe verkapseln und deren verwendung zur behandlung von malignen tumoren | |
| DE69820861T2 (de) | Teilchenförmige arzneimittelträger | |
| DE69122810T2 (de) | Liposomen | |
| DE60017783T2 (de) | Biomolekularer komplex,gebildet aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung | |
| DE3872875T2 (de) | Verfahren zur herstellung von liposomen. | |
| EP1796649A2 (de) | Nanotransportsystem mit dendritischer architektur | |
| DE3815473C2 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: NOVOSOM AG, 06120 HALLE, DE |
|
| 8304 | Grant after examination procedure | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |